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Type2diabetes mellitus(DM2)isincreasinginincidence,creatingworldwidepublichealthconcernsandimpactingmorbidityand
mortality rates. An increasing number of studies have demonstrated shared associationsbetween DM2 and malignancy, including
key clinical, biochemical, and metabolic commonalities. This paper will attempt to explore the relationship between the various
types ofcanceranddiabetes, the commonmetabolic pathwaysunderlying cancerdevelopment,andthe potentialimpact ofvarious
antidiabetes therapies on cancer risk.
1.Introduction
The association between diabetes and cancer was described
long before the 21st century, as far back as 1885 [1]. DM2
continues to increase in prevalence aﬀecting 17.9 million
Americans with 5.7 million undiagnosed, costing an esti-
mated 174 billion healthcare dollars [2]. Cancer, second only
toheart disease inmortality,is alsoontherisewith estimated
costs in the US of $263.8 billion [3]. These two high-impact
diseases share factors which inﬂuence their developmentand
progression, important in modifying each other’s outcome.
1.1. Clinical Factors Underlying Cancer Risk. Common non-
modiﬁable (age, sex, and race/ethnicity) and modiﬁable
(weight, diet, physical activity, tobacco use, and alcohol use)
risk factors underlie the development of cancer and DM2.
Figure 1(a) illustrates the general risk factors for cancer
development in diabetes. It is known that both DM2 and
cancer increase with age; those ≥55 years comprise almost
80% of newly diagnosed cancers and 23.1% of patients ≥
60 years develop DM2 compared to 10.7% of younger adults
[4, 5]. Men have slightly more cancer and diabetes compared
to women after adjusting for other risks [4–6]. African-
Americans as a subgroup appear hardest hit with regards
to cancer-related deaths, DM2, and obesity compared to
non-Hispanic white counterparts [4, 5]. Central obesity, a
marker of insulin resistance and a key player in both DM2
and the metabolic syndrome, has also been linked to breast,
colorectal, liver, and endometrial, malignancies [5]. Dietary
choices high in glycemic load and saturated fat and low in
ﬁber accompanied by reduced physical activity also increase
the risk for DM2 and malignancy, particularly for the colon,
endometrium and breast [5, 7]. Moreover, studies show that
tobacco and excess alcohol usage linked to cancer can also
worsen diabetes complications [5].
1.2. Types of Cancers Linked to DM2 and Common Metabolic
Pathways. Diabetes has been recognized as a key factor
contributing to the developmentof solid organ malignancies
including liver, pancreas, colorectal, breast, endometrial,
uterine, and bladder [3, 5, 8–18]. The two cancers showing
the strongest association to DM2 are those of the liver
[1, 5, 9, 18–20] and pancreas [1, 5, 18–20]. Not only does
there appear to be an association between DM2 and cancer,
but having both diagnoses may increase mortality, regardless
of the type of cancer [9, 21]. Studies performed in Japan,
Korea, and Hong Kong demonstrated increased cancer risk
[19, 20, 22]a n dm o r t a l i t y[ 19, 22] among participants with
DM2, especially those with poorly controlled DM2 based on
HbA1c [22] and fasting serum glucose levels [19]. A recent
meta-analysis of 23 articles indicated a 41% increase in can-
cer mortality related to endometrial, breast, and colorectal
cancer in patients with preexisting diabetes as compared to
normoglycemic individuals [21]. In the American Cancer2 Journal of Nutrition and Metabolism
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Figure 1: The “big picture” between DM2 and cancer. (a) The shared metabolic factors underlying both DM2 and cancer, including
visceral adiposity, inﬂammation, hyperglycemia, and hyperinsulinemia lead to (b) increased insulin receptor substrate (IRS) stimulating
the phosphorylation of Ras signalingproteins and potentially increasing tumor cell growth and proliferation. IRS-associated PI3K signaling
is compromised by insulin resistant states, such as in DM2, and downstream GLUT4 translocation is disrupted. This disruption drives
PI3K signaling towards AKT/mTOR. AKT and mTOR can aﬀect both the metabolic and mitogenic pathway, but because of the signaling
dysfunction, AKT and mTOR are driven towards the mitogenic pathway.
Society Cancer Prevention Study II [9] that enrolled over 1
million patients, adults with diabetes and cancer had greater
mortality. In contrast, increased mortality was not found in
subjects with diabetes in the National Health and Nutrition
Examination Survey Mortality Followup [23].
Considering the associations between diabetes and vari-
ous malignancies, can mechanisms related to diabetes devel-
opment predispose to oncogenic expression? There appears
to be a critical interplay between hyperglycemia, hyperinsu-
linemia,andadiposity,particularlycentraladiposity,creating
a low-grade chronic inﬂammatory state. These elements are
proposed to connect cancer developmentand progression to
DM2 which may also inﬂuence the response to anticancer
therapy.Sinceinsulin, glycemia,adiposity, andinﬂammation
can be modiﬁed by antidiabetes pharmacotherapy, a better
understanding of their pathophysiologic links to cancer may
allow us to more eﬀectively target DM2 treatment.
Insulin, because of its known mitogenic eﬀects, has been
implicated as a key mediator in the complex mechanisms
involved in carcinogenesis. Both insulin and insulin-like
growth factor-1 (IGF-1) have aﬃnity to both the insulin
receptor(IR)andIGF-1receptor(IGF-1R)becauseofsimilar
structural homology. But it is important to recognize that
insulin’s aﬃnity for the IR is upwards of 1000-fold greater
than for IGF-1R [24]. Both IGF-1 and IGF-1R tend to
have stronger mitogenic and antiapoptotic eﬀects, and the
hyperinsulinemia that occurs in insulin-resistant individuals
may enhance this eﬀect [1, 5, 18, 24]. Insulin may also
indirectly promote cancer development via IGF-1. Insulin
decreases IGF-binding protein-1, and possibly IGF-binding
protein 2, which may increase the bioactive form of the
growth factor, IGF-1 [18, 24] In addition, malignant cells
predominantly express the A isoform of the IR (IR-A) or
hybrid IR-A/IGF-1R forms, which have more mitogenic
eﬀects than the B isoform IR [5, 18, 25]. Thus, in the
hyperinsulinemic individual, insulin’s mitogenic properties
may further oncogenic proliferation.
Furthermore, hyperinsulinemia may ultimately upregu-
late the insulin mitogenic pathway compared to the insulin
metabolic pathway. Insulin resistant states such as obe-
sity, metabolic syndrome, and DM2 cause impairment of
downstream GLUT4 translocation by disruption of insulin
receptor substrate-1 (IRS-1) associated PI3K signaling in the
metabolic pathway of insulin [26]. Insulin, to a lesser extent
than IGF-1, stimulates cellular growth and protein synthesis
through the protein kinase B (PKB) system and activationJournal of Nutrition and Metabolism 3
of mTOR [27]. Abnormal IRS-1 phosphorylation from
overactivation of mTOR creates a negative feedback loop
that attenuates the metabolic pathway in hyperinsulinemia
[18, 27]. IRS-2 expression by insulin phosphorylation leads
to increased ERK activation, a mitogen-activated protein
kinase pathway (MAPK), because the mitogen pathways
mediated by mTOR and Ras remain intact [18, 26, 27]. This
drive towards the mitogen pathway with hyperinsulinemia
leads to enhanced cell growth and survival. Figure 1(b)
illustrates the potential molecular pathways, mediated by
insulin, which lead to cancer. Moreover, hyperglycemia may
not only promote tumorigenesis indirectly by stimulating
insulin production, but also may have a direct eﬀect, since
cancer cells depend on glycolysis for energy [6, 17].
Centraladiposity highly correlateswith insulinresistance
and is a key player in metabolic derangements associ-
ated with diabetes. Adipose tissue-derived cytokines, free
fatty acids, and other vascular factors released from the
visceral compartment have been shown to induce insulin
resistance, lipid abnormalities, glucose intolerance, and low
grade inﬂammation that collectively creates an environment
ripe for cancer development and progression. In contrast,
adiponectin is of particular interest for cancer prevention
because of its unique metabolic properties which include
the ability to decrease hepatic gluconeogenesis, to increase
insulin sensitivity, and to reduce adipogenic inﬂammation
[28–31]. Working in opposition to adiponectin are resistin,
visfatin, TNFα,IL-6, andMCP-1. These factors mayincrease
cancerrisk by perpetuating insulin resistance, hyperglycemia
and inﬂammation [25, 28–34]. The 30% mortality reduction
related primarily to cancer and cardiovascular events follow-
ing massive weight loss after bariatric surgery in morbidly
obese subjects enrolled in the Swedish obesity study cohort
further supports the contribution of adipocytokines in car-
cinogenesis [35]. However, the precise mechanisms related
to lower cancer risk following surgical weight loss remains
unclear.
Breastcancerisoneofthemorewidelystudiedmalignan-
cies with respect to its connection to diabetes. Some studies
showed an increased risk of breast malignancy in individuals
with diabetes [8–11, 14–16, 18], whereas others did not
[36–39]. Although most studies were retrospective case-
control or cohort studies [8–10, 14–18, 36–38], one of two
large-scale prospective studies of more than 97,000 Japanese
women showed no increase in breast cancer risk [20],
whereas another with more than 116,000 women enrolled in
the Nurses’ Health Study, showed a mild, but signiﬁcantly
increased, cancer risk with a hazard ratio of 1.17 (95% CI
of 1.01–1.35) in those with diabetes [11]. Additionally, many
studies demonstrate greater cancer risk in postmenopausal
women with DM2 than their younger, premenopausal
counterparts [10, 14, 21]. Elevations in plasma estrogen
levels have been associated with postmenopausal breast
cancer risk in the nondiabetes population [1, 34]. In insulin-
resistant postmenopausal women, elevated serum insulin
levelsreduce sex-hormone-binding globulin (SHBG),result-
ing in increased estrogen bioavailability possibly explaining
this increased risk [1, 5, 34, 40]. The elevation of free
estrogens is also seen in postmenopausal DM2 even after
adjusting for the degree of obesity [5, 34]. Furthermore,
insulin has been shown tobe mitogenic in human mammary
epithelial cells, but was less mitogenic compared to IGF-
1[ 24]. In obesity, IGF-1 is an important link to breast
cancer [34]. Hyperinsulinemia could stimulate IGF-1R and
hybrid receptors although the clinical signiﬁcance of this in
breast cancer development is still unclear. It is important to
remember that IGF-1 is much more mitogenic than insulin,
and an insulin concentration 100 times that of IGF-1 was
needed to elicit equivalent breast cancer cell growth [24]. In
vitro animal models showed IGF-1 to be a signiﬁcant risk
factor in mammary tumor onset and development [41].
A signiﬁcant risk for colorectal cancer in DM2 patients
as compared to those without diabetes has been reported in
a number of retrospective and prospective studiesexamining
this relationship. Some studies show an increased risk only
in men, whereas others document a risk in both genders
[18, 42–47]. As with breast cancer, the underlying factors
appear to be elevated glucose, insulin and IGF-1 levels. For
example, in vitro systems point to enhanced colonic tumor
cell growth with elevations of both insulin and IGF-1 levels
[48–51].Decreased IGFbinding proteins may also playa role
in colorectal cancer development as suggested by one [51]
but not other studies [50, 52, 53].
Becausetheliverandpancreasaretwomaintargetorgans
for insulin metabolism, it is not surprising that DM2 and
hepatocellular carcinoma share a link. The incidence of
hepatocellular carcinoma has been reported to be higher in
those with DM2 in both sexes, with a greater risk in men [1]
and in those with concomitant hepatitis C infection [18, 54–
61]. Some studies show that DM2 increases hepatocellular
cancer only in the presence of hepatitis or cirrhosis [56, 57,
59, 60], whereas others observe that the association exists in
the absence of those characteristics [18, 54, 58, 61].
Other cancers linked to diabetes and its metabolic fea-
tures include endometrial, pancreatic, kidney, and possibly
gastric malignancies [5, 42, 54, 62]. Older studies published
in the early 1990s have indicated that individuals with dia-
betes ≥5 years appear to have an increased risk of pancreatic
cancer [63, 64]. More recent studies show that pancreatic
cancer risk occurs within the ﬁrst decade of the diagnosis of
DM2,andsome arguethatthehighestrisk iswithin2-3years
of DM2 onset [65, 66]. Controversy regarding pancreatic
cancer has evolved from the “chicken or egg” issue: does
pancreatic cancer cause diabetes or does this malignancy
result from diabetes? Some investigators would argue that
diabetes is a result of pre-existing pancreatic cancer causing
destruction of ß-cells via tumor inﬁltration [65]. The tumor
b u r d e nw o u l dh a v et ob ee x t e n s i v ef o rap h y s i c a ll o s so f
islet cells to cause DM2. Newer hypotheses suggests that
DM2 results more from peripheral insulin resistance and
disruption of amylin secretion in β-cells [67, 68]f r o ma
paraneoplasticeﬀectofthetumorcells,ratherthanaphysical
destruction of β-cells. One epidemiologic case-control study
by Chari et al. suggest that pancreatic cancer may cause
DM2 through alteration of glucose metabolism in the liver
and skeletal muscle, thereby inducing glucose intolerance
[66]. Moreover, elevated glucose levels are associated with
increased pancreatic cancer mortality [63]. Regardless of the4 Journal of Nutrition and Metabolism
exact nature of the association, it is clear that a relationship
exists between DM2 and pancreatic cancer.
Interestingly, the presence of Helicobacter pylori may
increase gastric cancer risk [69–71] in diabetes, possibly
mediated through an insulin resistance/hyperinsulinemia
pathway [70]. Increase in gastrin levels, decrease in somato-
statin levels, and increase in neutrophilic and monocytic
inﬁltration of the gastric mucosa in patients with H. pylori
infection may lead to insulin resistance [70]. Eradication of
H. pylori may mitigate the gastric cancer risk [72]. However,
thepr evalenc eﬁndingsofH. pylori in DM2patientshasbeen
variable, and we do not yet clearly understand the clinical
implications in this population.
There are also studies arguing against an association
between diabetes and cancer, speciﬁcally for ovarian, lung,
and prostate malignancies [5, 42, 73, 74]. In prostate cancer,
DM2 appears to have a protective eﬀect, and like pancreatic
cancer, there is a temporal relationship, with the protective
eﬀect occurring later in DM2 [62, 74]. Circulating insulin
levels are inversely correlated with dihydrotestosterone,
testosterone, and SHBG. Thus, it has been proposed that
the lower testosterone levels that occur in DM2 may be a
mechanism of decreased prostate cancer risk [74]. However,
elevated circulating testosterone levels are not a consistent
ﬁnding associated with prostate cancer [5, 9, 62]. Another
suggested mechanism that may explain the time-associated
inverse relationship is the change in insulin levels as DM2
progresses. IGF-1 levels have been associated with increased
prostate cancer risk. Insulin downregulates IGF binding
protein 1, and as insulin levels decrease over time through
reduction in β-cell mass with DM2 disease progression,
there is less downregulation of IGF-binding protein 1. Since
IGF binding protein 1 controls the amount of IGF-1 free
levels,lesscirculatinginsulin mayindirectlymitigateprostate
cancer risk [9, 62, 74, 75].
The studies examining the relationship between DM2
and hematopoietic malignancies appear to show a positive
relationship between diabetes and hematopoietic cancers [6,
37], but this ﬁnding is not consistent in all studies [42, 76].
Major limitations of these studies include self-reported data
regarding the diagnosis of diabetes, which makes it diﬃcult
to clearly ascertain the exact links between diabetes and
hematopoietic cancers. Oxidative stress and cellular damage
related to hyperglycemia may be involved in the association
between the two [22, 77, 78]. One prospective cohort
study found a positive association between postload plasma
glucose levels in non-diabetes patients and non-Hodgkin’s
lymphoma in men anda 3-fold increased mortality risk from
multiple myeloma in women at the highest levelof post-load
plasma glucoselevels[78].Clearly,furtherstudiesare needed
in this arena.
1.3. Antidiabetes Therapy and Cancer Risk
1.3.1.Insulin AnaloguesandCancer. Insulinisaknownmito-
gen that stimulates the MAPK pathway leading to increases
in growth factors. In addition, insulin down-regulates IGF
binding proteins which may contribute tosex-steroid depen-
dent cancers in diabetes, particularly postmenopausal breast
and endometrial malignancies. In vitro studies have shown
thathighinsulinlevelscanaﬀectangiogenesisandpotentially
propagate tumor progression by stimulating the mitogen
pathway via both insulin and IGF receptors [92, 93]. A num-
ber of studies have examined the eﬀect of exogenous insulin
usage with cancer. These studies are summarized in Tables
1(b) and 1(c). An initial concern was raised by the provoca-
tive report of a retrospective German study suggesting an
increased cancer risk with glargine use [87]. Since then,
most large-scale studies have focused on glargine although
otherinsulin analogueshave beenstudiedas well. The results
from retrospective studies are conﬂicting, with some studies
showing an increased risk of malignancy [22, 82, 85–87, 94],
whereas others [82, 83, 88, 88, 89, 89, 90, 90, 91, 91]d i dn o t .
In vitro studies may help explain the basis of the concern
regarding insulin analogues, particularly glargine. Weinstein
et al. studied the comparative mitogenic eﬀect at supra-
physiologic doses of regular insulin and insulin analogues
glargine, detemir, lispro, and aspart to IGF-1 in cancer-
derived cell lines from colon (HCT116), prostate (PC3), and
breast(MCF-7)[95].Theinsulinanaloguesglargine,detemir
and lispro stimulated proliferation with a dose-dependent
eﬀect of all three cell lines but less than IGF-1. Regular and
aspart insulin had the lowest mitogenic eﬀect compared to
the other insulin analogues and IGF-1 [95]. Furthermore,
studies [95–97] indicate that glargine induced MCF-7 breast
cancer cell proliferation to a signiﬁcant level compared to
the MCF-10 cells, but the stimulation was less compared to
IGF-1. This discrepancy in responses between the two breast
cancer cell lines is attributed to the diﬀerences in relative
cellular IGF-1R and IR expression [24]. However, one study
by Liefvendahl et al. found that glargine had little to no
increased mitogenic eﬀect in malignant cell lines for breast
cancer (MCF-7 and SKBR-3) or osteosarcoma (SaOS-2)
compared to human insulin [93], The caveat in this contro-
versymayrelatetoadose-timeexposuretoinsulintreatment,
particularly with glargine; that is, cumulative insulin intake
over time may potentially increase the cancer risk and
mortality [98]. Because of all the controversy, the FDA has
concluded that glargine is safe, but it is awaiting longer-term
prospective studies regarding malignancy potential.
1.4. Oral Hypoglycemic Agents and Cancer. Agents which
treat or prevent DM2 might be expected to inﬂuence risk
of cancer favorably. Current oral agents that treated DM2
fall into two broad general categories: insulin providing (sec-
retagogues, metiglinides, and incretin analogs) and insulin-
sensitizing (metformin and thiazolidinediones). The insulin
sensitizers, metformin, and thiazolidinediones (TZDs) are
promising cancer therapies, because they not only lower glu-
cose, insulin and fatty acid levels, but also may have unique
anticarcinogenic properties that will be discussed below.
1.4.1. Insulin Sensitizers (Biguanides and Thiazolidinediones).
Metformin is generally used as a ﬁrst-line agent for DM2
treatment; it decreases hepatic glucose output and increases
glucose disposal in muscle, thereby reducing levels of
circulating serum glucoseand insulin levels.Epidemiological
studies in diabetic patients have shown that metformin mayJournal of Nutrition and Metabolism 5
Table 1: Cancer risk with oral agents and insulin therapy.
(a) Population studies of oral antidiabetic medications and cancer risk
Study Publish year country
(study Yrs)
Increased risk (OR with 95% CI) Cancer type(s)
Evans et al. [79]
case-control
hospitalized patients
2005 Scotland
(1993–2001)
No
(i) Metformin (OR 0.77)
None speciﬁed (All
incidence of cancers)
Bowker et al. [80]
retrospective
2006 Canada
(1991–1996)
Yes
(i) SFU compared to
metformin (HR 1.3,
P = .012)
(ii) Insulin (HR 1.9,
P = .0001)
None speciﬁed (Looked
speciﬁcally at
cancer-related mortality
and not cancer type.)
Monami et al. [81]
case control
2009 Italy
(1998–2004)
After >36 months of use:
No
(i) Acarbose (OR 0.77)
(ii) Glicazide (OR 0.40)
(iii) Glitazones (OR
1.05)
(iv) Insulin (OR 0.91)
(v) Metformin (OR
0.28)
(vi) Other SFU (OR
1.05)
(vii) Repaglinide (OR
0.87)
After >36 months of use:
Yes
(i) Glibenclamide (OR
2.62, P = .009)
GI breast
genital tract
(male/female)
pancreas
lung
Li et al. [64]c a s e
control hospitalized
patients
2009 United States
(2004–2008)
No
(i) Metformin (OR 0.38)
Yes
(i) Insulin (OR 4.99)
(ii) Insulin
secretagogues (OR 2.52)
(iii) TZD’s (OR 1.55)
Pancreas
(adenocarcinoma)
Mannucci et al. [82]
case control
2010 Italy
(1998–2007)
No
(i) Other insulin: lispro,
aspart, and human
insulin
(ii) Metformin
Yes
(i) ≥0.3IU/kg/d of
glargine
GI
hepatic
pancreatic
lung
leukemia/lymphoma
breast
urogenital
prostate
20 “other cancers”
(b) Meta-analyses of insulin and cancer
Study
Publish Year
country
(study Yrs)
Total number
of studies Total (n) Insulin
analyzed
Increased risk?
Dejgaard et al. [83]
Meta-analysis of
randomized controlled
Novo Nordisk trials
Type I and Type II
2009
Denmark 21 8693 Detemir
NPH glargine
No
(i) Glargine and
detemir had
similarrisk
Yes
(i) NPH had
more risk than
detemir
Home et al. [84]
Meta-analysis of
randomized controlled
SanoﬁAventis trials
Type I and Type II
2009 United
Kingdom 31 10,880 Glargine No6 Journal of Nutrition and Metabolism
(c) Population studies of insulin and cancer risk
Study
Publish year
country
(study Yrs)
Total (n) Insulin analyzed Increased risk?
Yang et al. [85]
retrospective
cohort
2004 United
Kingdom
(1987–2002)
24,918
Insulin analogues
(types not
speciﬁed)
Yes
colorectal cancer
Donadon et al.
[86] case control
2008 Italy
(1994–2006) 955
Insulin analogues
(types not
speciﬁed)
Yes
hepatocellular
cancer in
insulin-treated
males
Hemkens et al.
[87] retrospective
cohort
2009 German
(1998–2005) 127,031
Aspart, glargine,
human insulin,
lispro
Yes
may be dose
dependent
Jonassonet al. [88]
retrospective
cohort
2009 Sweden
(2005–2007) 114,841 Glargine No
Colhoun et al. [89]
retrospective
cohort
2009 Scotland
(2002–2005) 36,254 Glargine No
Currie et al. [90]
retrospective
cohort
2009 United
Kingdom
(2000–2005)
62,809
Insulin analogues
(types not
speciﬁed) oral
agents
No
Rosenstock et al.
[91]r a n d o m i z e d
control
2009 United
States (5 years) 1017 NPH, glargine No
Yang et al. [22]
retrospective
cohort
2010 Hong
Kong
(1996–2005)
4623
Insulin analogues
(types not
speciﬁed)
No
be neutral [99]o rp r o t e c t i v eo fc a n c e rr i s k[ 64, 80, 81, 90,
100, 101]. Table 1(a) displays data from several population
studies examining oral anti-diabetes agents and cancer risk.
A meta-analysis of diabetes studies with 4,042 cancer events
and 529 cancer deaths demonstrated a 31% reduction
in relative risk with metformin versus other antidiabetic
drugs [102]. In vitro cell culture studies as well as animal
studies have clearly demonstrated antitumor properties of
metformin [103–108]. Mice mammary tumor growth was
reduced by metformin, indicating a potential chemothera-
peuticrole in human breast cancertherapy [103]. The mech-
anisms for the anti-tumor eﬀects of metformin include an
inhibition of cell proliferation, decrease cancer proliferation,
with partial cell-cycle arrest in oncogenic cell lines with
the activation of 5  adenosine monophosphate-activated
protein (AMP) and AMP-kinase (AMPK) [5]. AMPK is an
essential mediator of the tumor suppressor LKB1. Because
of its properties, AMPK could be used to suppress cancer
cells containing loss-of-function LKB1 mutations, active
B-Raf mutations, or in cancers associated with metabolic
syndrome. The activation of AMPK reprograms cellular
metabolism by acting on mTORC1, p53, fatty acid synthase,
andothermoleculesinvolvedwithregulating cellgrowthand
metabolism [106].
Thiazolidinediones, or TZDs as they are more com-
monly known (i.e., rosiglitazone and pioglitazone), bind to
peroxisome proliferator-activated receptor (PPAR) gamma
(γ) receptor molecules inside the cell nucleus which, when
activated, result in transcription of a variety of genes. PPAR
γ is an adipocyte transcription factor, stimulating diﬀer-
entiation of adipocytes as well as inhibiting inﬂammatory
cytokine production [109]. This class of drugs reduces
insulin levels by enhancing insulin action. PPAR γ activation
results in reduced free fatty acids and eicosanoids and
inhibition of VEGF-induced angiogenesis, amongst other
actions [110]. Like metformin, TZDs inhibit cancer cell
growth, potentiation, and proliferation, inducing apoptosis,
at the in vitro level [5, 34]. Conversely, there are studies
in rodents showing increased tumorigenesis by PPAR γ
agonists. Epidemiologic studies have shown inconclusive
resultswith arecent meta-analysis [111]showingnoeﬀecton
malignancyrisk.Overall,studiesexaminingTZDsarelimited
because of the short-term exposure and limited cases of can-
cer at speciﬁc sites. A phase 1 trial using thiazolidinediones
in combination with chemotherapy for refractory cancers
was negative, butlarge-scale controlledstudiesare warranted
[5, 112].
1.4.2. Secretagogues (Sulfonylureas and Meglitinides). Secret-
agogues stimulate insulin production by binding to speciﬁc
cell receptors that result in depolarization of pancreatic
beta cells [81]. Sulfonylurea (SFU) use, like insulin, hasJournal of Nutrition and Metabolism 7
been implicated in cancer risk. Glitinides are less commonly
used, and their association with cancer is unknown. A few
observational studies have associated SFU use with higher
cancer risk. However, the limitations of these studies relate
to the lack of power given the small numbers of cancer
events [80]. In addition, most studies have not addressed
diﬀerences between the various SFU agents with one small
study suggesting variable eﬀects [81]. The eﬀect of oral
diabetic agents on incidence of malignancy was extracted
from two randomized controlled trials, ADOPT (A Diabetes
Outcome Progression Trial) and RECORD (Rosiglitazone
Evaluated for Cardiovascular Outcomes and Regulation of
Glycaemia in Diabetes). Despite a total study exposure of
39,000person/years overa 4-to 6-yearduration, neithertrial
demonstrated an advantage of metformin over rosiglitzone
or SFUs on cancer rates. The hazard ratio for metformin
versus rosiglitazone was close to 1.0 in both studies [99].
However, the data regarding SFUs is less clear with a
nonstatistically signiﬁcant reduction of 22% (95% CI 0.53–
1.14) in ADOPT for metformin versus SFUs and 25% (95%
CI0.85–1.18)inRECORDforrosiglitazoneversusSFUs[99].
1.4.3. Alpha Glucosidase Inhibitors (Acarbose). Acarbose, an
α-glucosidase inhibitor, curbs postprandial blood glucose
excursions by inhibiting the enzymatic degradation of car-
bohydrates in the small intestines brush border. Although
cancer risk information regarding α-glucosidase inhibitors
is limited, one study suggests that acarbose may augment
butyrate, a colonocyte energy source with anticolon cancer
eﬀects. This particular study showed promising results of
acarbose use toenhance fecal butyrateconcentrations, which
may favorably aﬀect colonic neoplasia [113].
1.4.4. DPP-IV Inhibitors and GLP-1 Agonists. Dipeptidyl
peptidase-IV (DPP-IV) inhibitors, as well as glucagon-like
peptide-1(GLP-1)agonists,are relativelynewmedicationsin
thearsenaloftreatmentofDM2.Sitagliptin,oneoftwoavail-
able DPP-IV inhibitors in the US, initially made its debut
in 2006 followed by the release of saxagliptin in 2009. The
noninsulin injectable GLP-1 agonists, exenatide and liraglu-
tide, were ﬁrst introduced in the US in 2005, with a once-
weekly option on the horizon. These therapies are eﬀective
in preserving ß-cell mass by inhibiting apoptosis as well as
improving islet cell function [114, 115]. GLP-1 is an incretin
hormone that stimulates up to 70% of glucose-dependent
insulin secretion after an oral stimulus, and in non-DM2
patients, there is a quickﬁrst-phase insulin surge followed by
a longer second-phase response. DM2 patients have approxi-
mately 80% decreased ß-cell function as a result of increased
cell death from the oxidative stress of persistent hyper-
glycemia[114]. Subsequently,the ﬁrst phase of insulin is lost
in DM2. GLP-1 receptor agonists and the DPP-IV inhibitors,
which inhibit theenzymatic breakdown ofendogenousGLP-
1, can restore ß-cell sensitivity to glucose, increase ß-cell
mass, and improve overall islet cell function [114, 115].
Their relatively short-term use clinically does not permit
meaningful data on malignancy potential or risks. Thus,
only in vitro and animal studies may be used to address a
potential risk. DPP-IV has a complex role in relationship to
cancer and may inﬂuence all stages of cancer from apoptosis,
migration, invasion, and metastasis to even chemotherapy
sensitivity [116]. Sitagliptin showed increased pancreatic
ductal hyperplasia in a small rodent model study [5].
Increased ductal cell turnover and ductal metaplasia may
predispose to pancreatic cancer risk although one short-
term study involving human pancreatic cancer cell lines did
not result in cell proliferation with activation of GLP-1R
signaling. This lack of cell proliferation even after activation
of functional GLP-1R may be a result of GLP-1R expression
in the transduction pathway activation in pancreatic cancer
cells [117]. Of the two GLP-1 agonists, liraglutide was
associated with thyroid C-cell hyperplasia/tumor growth in
rodents mediated by GLP-1 receptor agonist stimulating
calcitonin gene expression [5, 118]. However, humans have
shown low GLP-1 receptor expression in thyroid C-cells,
which may be an indication of species-speciﬁc diﬀerences in
GLP-1 receptor expression [118].
2.Conclusions
With the current diabetes pandemic running in parallel to
the one forobesity, there is agrowing need to identify patho-
physiologic links underlying cancer risk and mortality in
this high risk population. The diabetes/metabolic syndrome
certainly appears to increase the risk of certain malignancies,
including breast, endometrial, colorectal,hepatocellular, and
possibly others. SinceDM2 may be preventableand certainly
treatable with lifestyle modiﬁcation and pharmacotherapy,
cancer risk may also be lowered by these strategies. Certain
anti-diabetes therapies (e.g., biguanides) may become the
adjuvant chemotherapy of the future. However, large-scale
controlled trials are warranted. The role of exogenous
insulin administration for cancer risk in diabetes remains
controversial; further clinical trials are needed.
Abbreviations
DM2: Type 2 diabetes mellitus
BMI: Body mass index
IGF: Insulin-like growth factor
IR: Insulin receptor
Ras: Rat sarcoma protein
PKB: Protein kinase B
mTOR: mammalian target of rapamycin
TNF α: Tissue necrosis factor α
PI3K: Phosphatidylinositol-3 kinase
GLUT4: Glucose transporter type 4
MAPK: Mitogen-activated protein kinase
IL-6: Interleukin-6
Akt: Serine/threonine-speciﬁc protein kinase
MCP-1: Monocyte chemoattractant protein-1
VEGF: Vascular endothelial growth factor
AMP: 5  adenosine monophosphate activated
protein
IRS: Insulin receptor substrate
SFU: Sulfonylurea
TZD: Thiazolidinedione
GLP-1: Glucagon-like peptide-1.8 Journal of Nutrition and Metabolism
Disclosure
The authors have nothing to disclose.
Acknowledgment
T h ea u t h o r sa r eg r a t e f u lf o rt h et h o u g h t f u lr e v i e wa n d
editorial assistance of this paper by Dr. Charles Faiman,
M.D. S. R. Kashyap is supported by National Institutes of
Health, RO1 DK089547-01 NIDDK/NIH and grants from
the American Diabetes Association.
References
[1] A. Czyzyk and Z. X. Szczepanik, “Diabetes mellitus and
cancer,” European Journal of Internal Medicine, vol. 11, no.
5, pp. 245–252, 2000.
[2] “National Information Diabetes Clearinghouse. National
Diabetes Statistics,” 2007, http://diabetes.niddk.nih.gov/dm/
pubs/statistics/.
[3] American Cancer Society, “Cancer Facts and Figures,” 2009,
http://www.cancer.org/Research/CancerFactsFigures/cancer-
facts-ﬁgures-2009.
[4] American Diabetes Association, http://www.diabetes.org/
diabetes-basics/diabetes-statistics/.
[ 5 ]E .G i o v a n n u c c i ,D .M .H a r l a n ,M .C .A r c h e re ta l . ,“ D i a b e t e s
and cancer: a consensus report,” CA Cancer Journal for
Clinicians, vol. 60, no. 4, pp. 207–221, 2010.
[ 6 ] W .L e v i n e ,A .R .D y e r ,R .B .S h e k e l l e ,J .A .S c h o e n b e r g e r ,a n d
J. Stamler, “Post-load plasma glucose and cancer mortality
in middle-aged men and women. 12-year follow-up ﬁndings
of the Chicago Heart Association Detection Project in
Industry,” American journal of epidemiology, vol. 131, no. 2,
pp. 254–262, 1990.
[7] L. S. A. Augustin, S. Gallus, S. Franceschi et al., “Glycemic
index and load and risk of upper aero-digestive tract
neoplasms (Italy),” Cancer Causes and Control, vol. 14, no.
7, pp. 657–662, 2003.
[ 8 ]J .A .B a r o n ,E .W e i d e r p a s s ,P .A .N e w c o m be ta l . ,“ M e t a b o l i c
disorders and breast cancer risk (United States),” Cancer
Causes and Control, vol. 12, no. 10, pp. 875–880, 2001.
[ 9 ]S .S .C o u g h l i n ,E .E .C a l l e ,L .R .T e r a s ,J .P e t r e l l i ,a n d
M. J. Thun, “Diabetes mellitus as a predictor of cancer
mortality in a large cohort of US adults,” American Journal
of Epidemiology, vol. 159, no. 12, pp. 1160–1167, 2004.
[10] L.L.Lipscombe,P.J.Goodwin, B.Zinman,J.R. McLaughlin,
and J. E. Hux, “Diabetes mellitus and breast cancer: a
retrospective population-based cohort study,” Breast Cancer
Research and Treatment, vol. 98, no. 3, pp. 349–356, 2006.
[11] K. B. Michels, C. G. Solomon,F. B.Hu et al.,“Type 2 diabetes
and subsequent incidence of breast cancer in the nurses’
health study,” Diabetes Care, vol. 26, no. 6, pp. 1752–1758,
2003.
[ 1 2 ]E .F r i b e r g ,N .O r s i n i ,C .S .M a n t z o r o s ,a n dA .W o l k ,
“Diabetes mellitus and risk of endometrial cancer: a meta-
analysis,”Diabetologia, vol. 50, no. 7, pp. 1365–1374, 2007.
[13] K. E. Anderson, E. Anderson, P. J. Mink et al., “Diabetes
and endometrial cancer in the Iowa Women’s Health Study,”
Cancer Epidemiology Biomarkers and Prevention,v o l .1 0 ,n o .
6, pp. 611–616, 2001.
[ 1 4 ]R .T a l a m i n i ,S .F r a n c e s c h i ,A .F a v e r o ,E .N e g r i ,F .P a r a z z i n i ,
and C. La Vecchia, “Selected medical conditions and risk of
breast cancer,” British Journal of Cancer, vol. 75, no. 11, pp.
1699–1703, 1997.
[15] E. Weiderpass, G. Gridley, I. Persson, O. Nyr´ en, A. Ekbom,
and H. O. Adami, “Risk of endometrial and breast cancer
in patients with diabetes mellitus,” International Journal of
Cancer, vol. 71, no. 3, pp. 360–363, 1997.
[16] L. Wideroﬀ, G. Gridley, L. Mellemkjaer et al., “Cancer inci-
dence in a population-based cohort of patients hospitalized
with diabetes mellitus in denmark,” Journal of the National
Cancer Institute, vol. 89, no. 18, pp. 1360–1365, 1997.
[17] J. Yun, C. Rago, I. Cheong et al., “Glucose deprivation con-
tributes to the development of KRAS pathway mutations in
tumorcells,”Science,vol.325,no.5947,pp. 1555–1559,2009.
[18] P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri,
“Diabetes and cancer,” Endocrine-Related Cancer, vol. 16, no.
4, pp. 1103–1123, 2009.
[ 1 9 ] H A .J .S u n ,H .O h r r ,W .S .J a e ,E .Y .J i ,M .J i ,a n dJ .M .S a m e t ,
“Fasting serum glucose level and cancer risk in Korean men
and women,” Journal of the American Medical Association,
vol. 293, no. 2, pp. 194–202, 2005.
[20] M. Inoue, M. Iwasaki, T. Otani, S. Sasazuki, M. Noda, and
S. Tsugane, “Diabetes mellitus and the risk of cancer: results
from a large-scale population-based cohort study in Japan,”
Archives of Internal Medicine,vol.166,no.17,pp. 1871–1877,
2006.
[ 2 1 ]B .B .B a r o n e ,H .C .Y e h ,C .F .S n y d e re ta l . ,“ L o n g - t e r m
all-cause mortality in cancer patients with preexisting
diabetes mellitus: a systematic review and meta-analysis,”
Journal of the American Medical Association, vol. 300, no. 23,
pp. 2754–2764, 2008.
[ 2 2 ]X .Y a n g ,G .T .C .K o ,W .Y .S oe ta l . ,“ A s s o c i a t i o n so f
hyperglycemia and insulin usage with the risk of cancer in
type 2 diabetes: the Hong Kong diabetes registry,” Diabetes,
vol. 59, no. 5, pp. 1254–1260, 2010.
[23] K. Steenland, S. Nowlin, and S. Palu, “Cancer incidence in
the national health and nutrition survey I follow-up data:
diabetes, cholesterol, pulse, and physical activity,” Cancer
Epidemiology Biomarkers and Prevention,v o l .4 ,n o .8 ,p p .
807–811, 1995.
[24] T. P. Ciaraldi and T. Sasaoka, “Review on the in vitro
interaction of insulin glargine with the insulin/insulin-like
growth factor system: potential implications for metabolic
and mitogenic activities,” Hormone and Metabolic Research,
vol. 43, no. 1, pp. 1–10, 2011.
[25] A. Belﬁore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri,
“Insulin receptor isoforms and insulin receptor/insulin-like
growth factor receptor hybrids in physiology and disease,”
Endocrine Reviews, vol. 30, no. 6, pp. 586–623, 2009.
[26] K. Cusi, K. Maezono, A. Osman et al., “Insulin resistance
diﬀerentially aﬀects the PI 3-kinase- and MAP kinase-
mediated signaling in human muscle,” Journal of Clinical
Investigation, vol. 105, no. 3, pp. 311–320, 2000.
[27] S. G. Dann, A. Selvaraj, and G. Thomas, “mTOR Complex1-
S6K1 signaling: at the crossroads of obesity, diabetes and
cancer,” Trends in Molecular Medicine,v o l .1 3 ,n o .6 ,p p .
252–259, 2007.
[28] R. S. Ahima, “Metabolic actions of adipocyte hormones:
focus on adiponectin,” Obesity, vol. 14, supplement 1, pp.
9S–15S, 2006.
[29] R. S. Ahima, “Central actions of adipocyte hormones,”
Trends in Endocrinology and Metabolism,v o l .1 6 ,n o .7 ,p p .
307–313, 2005.Journal of Nutrition and Metabolism 9
[30] P. J. Havel, “Update on adipocyte hormones: regulation
of energy balance and carbohydrate/lipid metabolism,”
Diabetes, vol. 53, no. 1, pp. S143–S151, 2004.
[31] M. B. Jackson and R. S. Ahima, “Neuroendocrine and
metabolic eﬀects of adipocyte-derived hormones,” Clinical
Science, vol. 110, no. 2, pp. 143–152, 2006.
[32] K. Cusi, “The role of adipose tissue and lipotoxicity in the
pathogenesis of type 2 diabetes,” Current Diabetes Reports,
vol. 10, pp. 306–315, 2010.
[33] C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone
resistin links obesity to diabetes,” Nature, vol. 409, no. 6818,
pp. 307–312, 2001.
[ 3 4 ]I .W o l f ,S .S a d e t z k i ,R .C a t a n e ,A .K a r a s i k ,a n dB .K a u f m a n ,
“Diabetes mellitus and breast cancer,” Lancet Oncology,v o l .
6, no. 2, pp. 103–111, 2005.
[35] L. Sj¨ ostr¨ om, “Bariatric surgery and reduction in morbidity
andmortality:experiences fromtheSOSstudy,”International
Journal of Obesity, vol. 32, supplement 7, pp. S93–S97, 2008.
[36] H. A. Weiss, L. A. Brinton, N. A. Potischman et al., “Breast
cancer risk in young women and history of selected medical
conditions,” International Journal of Epidemiology, vol. 28,
no. 5, pp. 816–823, 1999.
[37] H. Hjalgrim, M. Frisch, A. Ekbom, K. O. Kyvik, M. Melbye,
and A. Green, “Cancer and diabetes—a follow-up study of
two population-based cohorts of diabetic patients,” Journal
of Internal Medicine, vol. 241, no. 6, pp. 471–475, 1997.
[ 3 8 ]C .L aV e c c h i a ,E .N e g r i ,S .F r a n c e s c h i ,B .D ’ A v a n z o ,a n dP .
Boyle, “A case-control study of diabetes mellitus and cancer
risk,” British Journal of Cancer, vol. 70, no. 5, pp. 950–953,
1994.
[39] P. J. Mink, E. Shahar, W. D. Rosamond, A. J. Alberg, and
A. R. Folsom, “Serum insulin and glucose levels and breast
cancer incidence: the atherosclerosis risk in communities
study,” American Journal of Epidemiology, vol. 156, no. 4, pp.
349–352, 2002.
[40] A. G. Renehan, M. Zwahlen, C. Minder, S. T. O’Dwyer, S.
M. Shalet, and M. Egger, “Insulin-like growth factor (IGF)-I,
IGF binding protein-3, and cancer risk: systematic review
and meta-regression analysis,” Lancet, vol. 363, no. 9418, pp.
1346–1353, 2004.
[41] Y. Wu,K. Cui,K. Miyoshiet al.,“Reduced circulatinginsulin-
like growth factor I levels delay the onset of chemically and
genetically induced mammarytumors,”Cancer Research,v ol.
63, no. 15, pp. 4384–4388, 2003.
[42] H. O. Adami, J. McLaughlin,A. Ekbom et al., “Cancer risk in
patients with diabetes mellitus,” Cancer Causes and Control,
vol. 2, no. 5, pp. 307–314, 1991.
[43] F. B. Hu, J. E. Manson, S. Liu et al., “Prospective study of
adult onset diabetes mellitus (type 2) and risk of colorectal
cancer in women,” Journal of the National Cancer Institute,
vol. 91, no. 6, pp. 542–547, 1999.
[ 4 4 ]C .L aV e c c h i a ,E .N e g r i ,A .D e c a r l i ,a n dS .F r a n c e s c h i ,
“Diabetes mellitus and colorectal cancer risk,” Cancer
Epidemiology Biomarkers and Prevention,v o l .6 ,n o .1 2 ,p p .
1007–1010, 1997.
[45] S. C. Larsson, E. Giovannucci, and A. Wolk, “Diabetes and
colorectal cancer incidence in the cohort of Swedish men,”
Diabetes Care, vol. 28, no. 7, pp. 1805–1807, 2005.
[46] S. C. Larsson, N. Orsini, and A. Wolk, “Diabetes mellitus
and risk of colorectal cancer: a meta-analysis,” Journal of the
National Cancer Institute, vol. 97, no. 22, pp. 1679–1687,
2005.
[ 4 7 ]A .S e o w ,J .M .Y u a n ,W .P .K o h ,H .P .L e e ,a n dM .C .Y u ,
“Diabetes mellitus and risk of colorectal cancer in the
Singapore Chinese health study,” Journal of the National
Cancer Institute, vol. 98, no. 2, pp. 135–138, 2006.
[48] S.H.Say dah,C.M.Loria,M.S.Eberhar dt,andF .L.Brancati,
“Abnormal glucose tolerance and the risk of cancer death
in the United States,” American Journal of Epidemiology,v o l .
157, no. 12, pp. 1092–1100, 2003.
[49] T.I.L.NilsenandL.J.Vatten,“Prospective studyofcolorectal
cancer risk and physical activity, diabetes, blood glucose and
BMI: exploring the hyperinsulinaemia hypothesis,” British
Journal of Cancer, vol. 84, no. 3, pp. 417–422, 2001.
[ 5 0 ]T .O .K e k u ,P .K .L u n d ,J .G a l a n k o ,J .G .S i m m o n s ,J .T .
Woosley,andR.S.Sandler,“Insulinresistance,apoptosis,and
colorectal adenoma risk,” Cancer Epidemiology Biomarkers
and Prevention, vol. 14, no. 9, pp. 2076–2081, 2005.
[51] R. Kaaks, P. Toniolo, A. Akhmedkhanov et al., “Serum
C-peptide, insulin-like growth factor (IGF)-I, IGF-binding
proteins, and colorectal cancer risk in women,” Journal of
the National Cancer Institute, vol. 92, no. 19, pp. 1592–1600,
2000.
[52] R. Palmqvist, P. Stattin, S. Rinaldi et al., “Plasma insulin,
IGF-binding proteins-1 and -2 and risk of colorectal cancer:
a prospective study in Northern Sweden,” International
Journal of Cancer, vol. 107, no. 1, pp. 89–93, 2003.
[53] S.H.Say dah,E.A.Platz,N.Rifai,M.N.P ollak,F .L.Brancati,
and K. J. Helzlsouer, “Association of markers of insulin and
glucose control with subsequent colorectal cancer risk,”
Cancer Epidemiology Biomarkers and Prevention, vol. 12, no.
5, pp. 412–418, 2003.
[54] A. B. De Gonzalez, E. Y. Ji, S. Y. Lee, A. P. Klein, and HA.
J. Sun, “Pancreatic cancer and factors associated with the
insulin resistance syndrome in the Korean cancer prevention
study,” Cancer Epidemiology Biomarkers and Prevention,v o l .
17, no. 2, pp. 359–364, 2008.
[55] J. A. Davila, R. O. Morgan, Y. Shaib, K. A. McGlynn, and
H. B. El-Serag, “Diabetes increases the risk of hepatocellular
carcinoma in the United States: a population based case
control study,” Gut, vol. 54, no. 4, pp. 533–539, 2005.
[ 5 6 ]H .B .E l - S e r a g ,P .A .R i c h a r d s o n ,a n dJ .E .E v e r h a r t ,“ T h e
role of diabetes in hepatocellular carcinoma: a case-control
study among United States Veterans,” American Journal of
Gastroenterology, vol. 96, no. 8, pp. 2462–2467, 2001.
[57] Y. Fujino, T. Mizoue, N. Tokui, and T. Yoshimura,
“Prospective study of diabetes mellitus and liver cancer
in Japan,” Diabetes/Metabolism Research and Reviews,v o l .
17, no. 5, pp. 374–379, 2001.
[58] M. M. Hassan, S. A. Curley, D. Li et al., “Association of
diabetes duration and diabetes treatment with the risk
of hepatocellular carcinoma,” Cancer, vol. 116, no. 8, pp.
1938–1946, 2010.
[59] H. Kuper, A. Tzonou,E. Kaklamaniet al.,“Tobacco smoking,
alcohol consumption and their interaction in the causation
ofhepatocellularcarcinoma,”International Journal ofCancer,
vol. 85, no. 4, pp. 498–502, 2000.
[60] H. E. Kuper, A. Tzonou, E. Kaklamaniet al., “Hepatitis B and
C viruses in the etiology ofhepatocellular carcinoma;a study
in Greece using third-generation assays,” Cancer Causes and
Control, vol. 11, no. 2, pp. 171–175, 2000.
[61] P.Lagiou,H.Kuper,S.O.Stuver,A.Tzonou,D.Trichopoulos,
and H. O. Adami, “Role of diabetes mellitus in the etiology
of hepatocellular carcinoma,” Journal of the National Cancer
Institute, vol. 92, no. 13, pp. 1096–1099, 2000.10 Journal of Nutrition and Metabolism
[62] E. Giovannucci, E. B. Rimm, M. J. Stampfer, G. A. Colditz,
and W. C. Willett, “Diabetes mellitus and risk of prostate
cancer (United States),” Cancer Causes and Control,v o l .9 ,
no. 1, pp. 3–9, 1998.
[63] D. Li and J. L. Abbruzzese, “New strategies in pancreatic
cancer: emerging epidemiologic and therapeutic concepts,”
ClinicalCancerResearch,vol.16,no.17,pp.4313–4318,2010.
[ 6 4 ]D .L i ,S .J .Y e u n g ,M .M .H a s s a n ,M .K o n o p l e v a ,a n dJ .L .
Abbruzzese, “Antidiabetic therapies aﬀect risk of pancreatic
cancer,” Gastroenterology, vol. 137, no. 2, pp. 482–488, 2009.
[65] L. Gullo, R. Pezzilli, A. M. Morselli-Labate et al., “Italian
Pancreatic Cancer Study Group. Diabetes and the risk of
pancreatic cancer,” The New England Journal of Medicine,
vol. 331, no. 2, pp. 81–84, 1994.
[66] S. T. Chari, C. L. Leibson, K. G. Rabe et al., “Pancreatic
cancer-associated diabetes mellitus: prevalence and temporal
association with diagnosis of cancer,” Gastroenterology,v o l .
134, no. 1, pp. 95–101, 2008.
[67] F. Wang, M. Herrington, J. Larsson, and J. Permert, “The
relationship between diabetes and pancreatic cancer,”
Molecular Cancer, vol. 2, article 4, 2003.
[68] F. Wang, J. Larsson, A. Abdiu et al., “Dissociated secretion of
islet amyloid polypeptide and insulin in serum- free culture
media conditioned by human pancreatic adenocarcinoma
cell lines,” International Journal of Pancreatology, vol. 21, no.
2, pp. 157–164, 1997.
[ 6 9 ]P .M .W e b b ,M .L a w ,C .V a r g h e s e ,a n dD .F o r m a n ,“ G a s t r i c
cancer and Helicobacter pylori: a combined analysis of 12
case control studies nested within prospective cohorts,” Gut,
vol. 49, no. 3, pp. 347–353, 2001.
[70] S. Aydemir, T. Bayraktaroglu, M. Sert et al., “The eﬀect of
Helicobacter pylori on insulin resistance,” Digestive Diseases
and Sciences,vol. 50, no. 11, pp. 2090–2093, 2005.
[71] H. Yamagata, Y. Kiyohara, K. Aoyagi et al., “Impact of
Helicobacter pylori infection on gastric cancer incidence in a
general Japanese population: the Hisayama Study,” Archives
of Internal Medicine, vol. 160, no. 13, pp. 1962–1968, 2000.
[72] R. Gen, M. Demir, and H. Ataseven, “Eﬀect of helicobacter
pylori eradication on insulin resistance, serum lipids and
low-grade inﬂammation,” Southern Medical Journal,v o l .
103, no. 3, pp. 190–196, 2010.
[73] A. I. Adler, N. S. Weiss, M. L. Kamb, and J. L. Lyon, “Is
diabetes mellitus a risk factor for ovarian cancer? A case-
control study in Utah and Washington (United States),”
Cancer Causes and Control, vol. 7, no. 4, pp. 475–478, 1996.
[ 7 4 ]C .R o d r i g u e z ,A .V .P a t e l ,A .M .M o n d u l ,E .J .J a c o b s ,M .J .
Thun, and E. E. Calle, “Diabetes and risk of prostate cancer
in a prospective cohort of US men,” American Journal of
Epidemiology, vol. 161, no. 2, pp. 147–152, 2005.
[ 7 5 ]M .A n z o ,L .J .C o b b ,D .L .H w a n ge ta l . ,“ T a r g e t e dd e l e t i o n
of hepatic Igf1 in TRAMP mice leads to dramatic alterations
in the circulating insulin-like growth factor axis but does not
reduce tumor progression,” Cancer Research,v o l .6 8 ,n o .9 ,
pp. 3342–3349, 2008.
[76] G. D. Smith, M. Egger, M. J. Shipley, and M. G. Marmot,
“Post-challenge glucose concentration, impaired glucose
tolerance, diabetes, and cancer mortality in men,” American
Journal of Epidemiology, vol.136, no. 9, pp. 1110–1114,1992.
[77] P. Stattin, O. Bj¨ or, P. Ferrari et al., “Prospective study of
hyperglycemia and cancer risk,” Diabetes Care,v o l .3 0 ,n o .3 ,
pp. 561–567, 2007.
[ 7 8 ]B .C .H .C h i u ,S .M .G a p s t u r ,P .G r e e n l a n d ,R .W a n g ,a n dA .
Dyer, “Body mass index, abnormal glucose metabolism, and
mortality from hematopoietic cancer,” Cancer Epidemiology
Biomarkers and Prevention, vol. 15, no. 12, pp. 2348–2354,
2006.
[ 7 9 ]J .M .M .E v a n s ,L .A .D o n n e l l y ,A .M .E m s l i e - S m i t h ,D .R .
Alessi, and A. D. Morris, “Metformin and reduced risk of
cancer in diabetic patients,” British Medical Journal, vol. 330,
no. 7503, pp. 1304–1305, 2005.
[80] S. L. Bowker, S.R. Majumdar, P. Veugelers, andJ. A. Johnson,
“Increased cancer-related mortality for patients with type
2 diabetes who use sulfonylureas or insulin,” Diabetes Care,
vol. 29, no. 2, pp. 254–258, 2006.
[81] M. Monami, C. Lamanna, D. Balzi, N. Marchionni, and
E. Mannucci, “Sulphonylureas and cancer: a case-control
study,” Acta Diabetologica, vol. 46, no. 4, pp. 279–284, 2009.
[ 8 2 ]E .M a n n u c c i ,M .M o n a m i ,D .B a l z ie ta l . ,“ D o s e so fi n s u l i n
and its analogues and cancer occurrence in insulin-treated
type 2 diabetic patients,” Diabetes Care, vol. 33, no. 9, pp.
1997–2003, 2010.
[83] A. Dejgaard, H. Lynggaard, J. R˚ astam, and M. Krogsgaard
Thomsen, “No evidence of increased risk of malignancies in
patients with diabetes treated with insulin detemir: a meta-
analysis,”Diabetologia, vol. 52, no. 12, pp. 2507–2512, 2009.
[84] P. D. Home and P. Lagarenne, “Combined randomised
controlled trial experience of malignancies in studies
using insulin glargine,” Diabetologia, vol. 52, no. 12, pp.
2499–2506, 2009.
[85] Y. U. X. Yang, S. Hennessy, and J. D. Lewis, “Insulin therapy
and colorectal cancer risk among type 2 diabetes mellitus
patients,” Gastroenterology, vol. 127, no. 4, pp. 1044–1050,
2004.
[86] V. Donadon, M. Balbi, P. Casarin, A. Vario, and A. Alberti,
“Association between hepatocellular carcinoma and type 2
diabetes mellitus in Italy: potential role of insulin,” World
Journal of Gastroenterology, vol. 14, no. 37, pp. 5695–5700,
2008.
[87] L. G. Hemkens, U. Grouven, R. Bender et al., “Risk of
malignancies in patients with diabetes treated with human
insulin or insulin analogues: a cohort study,” Diabetologia,
vol. 52, no. 9, pp. 1732–1744, 2009.
[88] J. M. Jonasson, R. Ljung, M. Talb¨ ack, B. Haglund, S.
Gudbj¨ ornsd` ottir, and G. Steineck, “Insulin glargine use and
short-term incidence of malignancies-a population-based
follow-up study in Sweden,” Diabetologia,v o l .5 2 ,n o .9 ,p p .
1745–1754, 2009.
[89] H. M. Colhoun, “Use of insulin glargine and cancer
incidence in Scotland: a study from the Scottish diabetes
research network epidemiology group,” Diabetologia, vol. 52,
no. 9, pp. 1755–1765, 2009.
[90] C. J. Currie, C. D. Poole, andE. A. M. Gale, “The inﬂuence of
glucose-lowering therapies on cancer risk in type 2 diabetes,”
Diabetologia, vol. 52, no. 9, pp. 1766–1777, 2009.
[ 9 1 ]J .R o s e n s t o c k ,V .F o n s e c a ,J .B .M c G i l le ta l . ,“ S i m i l a rr i s k
of malignancy with insulin glargine and neutral protamine
Hagedorn (NPH) insulin in patients with type 2 diabetes:
ﬁndings from a 5 year randomised, open-label study,”
Diabetologia, vol. 52, no. 9, pp. 1971–1973, 2009.
[92] K. L. Rensing, F. M. Houttuijn Bloemendaal, E. M. Weijers
et al., “Could recombinant insulin compounds contribute
to adenocarcinoma progression by stimulating local
angiogenesis?”Diabetologia,vol.53,no.5,pp.966–970,2010.Journal of Nutrition and Metabolism 11
[93] E. Liefvendahl and H. J. Arnqvist, “Mitogenic eﬀect of the
insulin analogue glargine in malignant cells in comparison
with insulin and IGF-I,” Hormone and Metabolic Research,
vol. 40, no. 6, pp. 369–374, 2008.
[94] V. Donadon, M. Balbi, M. Ghersetti et al., “Antidiabetic
therapy and increased risk of hepatocellular carcinoma in
chronic liver disease,” World Journal of Gastroenterology,v o l .
15, no. 20, pp. 2506–2511, 2009.
[95] D. Weinstein, M. Simon, E. Yehezkel, Z. Laron, and H.
Werner, “Insulin analogues display IGF-I-like mitogenic
and anti-apoptotic activities in cultured cancer cells,”
Diabetes/Metabolism Research and Reviews,v o l .2 5 ,n o .1 ,p p .
41–49, 2009.
[ 9 6 ]A .S h u k l a ,J .G r i s o u a r d ,V .E h e m a n n ,A .H e r m a n i ,H .
Enzmann, and D. Mayer, “Analysis of signaling pathways
related to cell proliferation stimulated by insulin analogs in
human mammary epithelial cell lines,” Endocrine-Related
Cancer, vol. 16, no. 2, pp. 429–441, 2009.
[97] D. Mayer, A. Shukla, and H. Enzmann, “Proliferative eﬀects
of insulin analogues on mammary epithelial cells,” Archives
of Physiology and Biochemistry, vol. 114, no. 1, pp. 38–44,
2008.
[ 9 8 ]S .L .B o w k e r ,Y .Y a s u i ,P .V e u g e l e r s ,a n dJ .A .J o h n s o n ,
“Glucose-lowering agents and cancer mortality rates in
type 2 diabetes: assessing eﬀects of time-varying exposure,”
Diabetologia, vol. 53, no. 8, pp. 1631–1637, 2010.
[99] P. D. Home, S. E. Kahn, N. P. Jones, D. Noronha, H. Beck-
Nielsen, and G. Viberti, “Experience of malignancies with
oral glucose-lowering drugs in the randomised controlled
ADOPT (A Diabetes Outcome Progression Trial) and
RECORD (Rosiglitazone Evaluated for Cardiovascular
Outcomes and Regulation of Glycaemia in Diabetes) clinical
trials,” Diabetologia, vol. 53, no. 9, pp. 1838–1845, 2010.
[100] J. M. M. Evans, S. A. Ogston, A. Emslie-Smith, and A.
D. Morris, “Risk of mortality and adverse cardiovascular
outcomesintype 2diabetes: acomparisonofpatients treated
with sulfonylureas and metformin,” Diabetologia,v o l .4 9 ,n o .
5, pp. 930–936, 2006.
[101] G. Libby, L. A. Donnelly, P. T. Donnan, D. R. Alessi, A.
D .M o r r i s ,a n dJ .M .M .E v a n s ,“ N e wu s e r so fm e t f o r m i n
are at low risk of incident cancer: a cohort study among
people with type 2 diabetes,” Diabetes Care,v o l .3 2 ,n o .9 ,
pp. 1620–1625, 2009.
[102] A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin
and cancer risk in diabetic patients: a systematic review and
meta-analysis,”Cancer Prevention Research,v o l .3 ,n o .1 1 ,p p .
1451–1461, 2010.
[103] V. N. Anisimov, L. M. Berstein, P. A. Egormin et al., “Eﬀect
of metformin on life span and on the development of spon-
taneous mammary tumors in HER-2/neu transgenic mice,”
Experimental Gerontology, vol. 40, no. 8-9, pp. 685–693,
2005.
[104] V. N. Anisimov, P. A. Egormin, T. S. Piskunova et al.,
“Metformin extends life span of HeR-2/neu transgenic mice
and in combination with melatonin inhibits growth of
transplantable tumors in vivo,” Cell Cycle,v o l .9 ,n o .1 ,p p .
188–197, 2010.
[105] L. A. Cantrell, C. Zhou, A. Mendivil, K. M. Malloy, P. A.
G e hrig,andV .L.Bae - J u mp ,“ M e t f orminisap ot e ntinhib it or
of endometrial cancer cell proliferation-implications for a
novel treatment strategy,” Gynecologic Oncology, vol. 116, no.
1, pp. 92–98, 2010.
[106] E. Rozengurt, J. Sinnett-Smith, and K. Kisfalvi, “Crosstalk
between insulin/insulin-like growth factor-1 receptors and
G protein-coupled receptor signaling systems: a novel target
for the antidiabetic drug metformin in pancreatic cancer,”
Clinical Cancer Research, vol. 16, no. 9, pp. 2505–2511, 2010.
[107] A. Tomimoto, H. Endo, M. Sugiyama et al., “Metformin
suppresses intestinal polyp growth in Apc mice,” Cancer
Science, vol. 99, no. 11, pp. 2136–2141, 2008.
[108] Y. Zhuang and W. K. Keith, “Cell cycle arrest in Metformin
treated breast cancer cells involves activation of AMPK,
downregulation of cyclin D1, and requires p27 or p21,”
Journal of Molecular Signaling, vol. 3, article 18, 2008.
[109] A. Majuri, M. Santaniemi, A. Kunnari et al., “Rosiglitazone
treatment increases plasma levels of adiponectin and
decreases levels of resistin in overweight women with PCOS:
a randomized placebo-controlled study,” European Journal of
Endocrinology, vol. 156, no. 2, pp. 263–269, 2007.
[110] S. K. Vijay, M. Mishra, H. Kumar, and K. Tripathi, “Eﬀect of
pioglitazone and rosiglitazone on mediators of endothelial
dysfunction, markers of angiogenesis and inﬂammatory
cytokines in type-2 diabetes,” Acta Diabetologica, vol. 46, no.
1, pp. 27–33, 2009.
[111] M. Monami,C. Lamanna, N. Marchionni, and E. Mannucci,
“Rosiglitazone and risk of cancer: a meta-analysis of
randomized clinical trials,” Diabetes Care,v o l .3 1 ,n o .7 ,p p .
1455–1460, 2008.
[112] W. L. Read, M. Q. Baggstrom, P. M. Fracasso, and R.
Govindan, “A phase I study of bexarotene and rosiglitazone
in patients with refractory cancers,” Chemotherapy, vol. 54,
no. 3, pp. 236–241, 2008.
[113] G. A. Weaver, C. T. Tangel, J. A. Krause et al., “Biomarkers of
humancoloniccellgrowthareinﬂuenced diﬀerentlybyahis-
tory of colonic neoplasia and the consumption of acarbose,”
Journal of Nutrition, vol. 130, no. 11, pp. 2718–2725, 2000.
[114] T. Vilsbøll, “The eﬀects of glucagon-like peptide-1 on
the beta cell,” Diabetes, Obesity and Metabolism, vol. 11,
supplement 3, pp. 11–18, 2009.
[115] T. Salvatore, O. Carbonara, D. Cozzolino, R. Torella, and F.
C. Sasso, “Progress in the oral treatment of type 2 diabetes:
update on DPP-IV inhibitors,” Current Diabetes Reviews,v o l .
5, no. 2, pp. 92–101, 2009.
[116] T. Stulc and A. Sedo, “Inhibition of multifunctional
dipeptidyl peptidase-IV: is there a risk of oncological and
immunological adverse eﬀects?” Diabetes Research and
Clinical Practice, vol. 88, no. 2, pp. 125–131, 2010.
[117] J. A. Koehler and D. J. Drucker, “Activation of glucagon-like
peptide-1 receptor signaling does not modify the growth or
apoptosis of human pancreatic cancer cells,” Diabetes,v o l .
55, no. 5, pp. 1369–1379, 2006.
[118] L. B. Knudsen, L. W. Madsen, S. Andersen et al., “Glucagon-
like peptide-1 receptor agonists activate rodent thyroid
C-cells causing calcitonin release and C-cell proliferation,”
Endocrinology, vol. 151, no. 4, pp. 1473–1486, 2010.